California Life Sciences’ Statement on HHS Clinical Trial Effort

For years, California Life Sciences has warned that America’s biomedical leadership is not guaranteed — that China’s deliberate, state-directed strategy to dominate clinical research, recruit top talent, and accelerate drug development poses a genuine threat to U.S. leadership in medical innovation.

HHS’s plan to mobilize FDA, NIH, ARPA-H, and other agencies in a coordinated effort to restore U.S. leadership in clinical trials is the strategic, targeted response the moment requires. We commend the Administration for its commitment to ensuring that America remains the global destination for biomedical discovery —where research institutions, innovators, and patients waiting for treatments can all thrive. We look forward to working with the Administration to turn this commitment into results for patients.

— Mike Guerra, President & CEO, California Life Sciences